COMMUNIQUÉS West-GlobeNewswire

Oasmia has completed a directed share issue of approximately 165 MSEK
04/03/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the Company has carried out a placing of shares in the Company, through a directed issue of 22,948,535 shares, corresponding to [...]
Nexstim Plc Publishes 2018 Annual Report
04/03/2019
Company announcement, Helsinki, 04.03.2019 at 09.15 Finnish time (EET) Nexstim Plc Publishes 2018 Annual Report Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), the targeted neuromodulation company [...]
NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2018
04/03/2019
Company announcement, Helsinki, 4 March 2019 at 9:00 am NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2018 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and [...]
Ossur Hf : Candidates to the Board of Directors
04/03/2019
Announcement no. 14/2019 4 March 2019 Candidates to the Board of Directors Enclosed are details on the candidates to the Board of Directors of Össur hf., to be elected at the Annual General Meeting held on Thursday, 7 [...]
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
04/03/2019
Biogen to acquire Nightstar for US$ 25.50 per share in cash Transaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar [...]
Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
04/03/2019
Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that [...]
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
04/03/2019
Single dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses Data support initiation of part 2 of [...]
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
04/03/2019
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3[1] Results [...]
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
04/03/2019
SOUTH SAN FRANCISCO, Calif., TAIWAN, SHEN YANG, China and HONG KONG, March 04, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company [...]
Get Answers to Your Dermatology Questions with a New Series from Excelin Medical Spa
04/03/2019
Dr. Victoria Negrete and the Excelin Medical Spa team welcome guests to live events exploring CoolSculpting, wrinkles, and more in March APPLETON, Wis., March 03, 2019 (GLOBE NEWSWIRE) -- With the understanding that [...]
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
02/03/2019
– CAMP-1 and CAMP-2 trials of VP-102 for the treatment of molluscum contagiosum successfully met their primary endpoints – – Molluscum contagiosum is a highly contagious , significantly undertreated viral skin disease [...]
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
02/03/2019
-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids -- -- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of treatment [...]
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
01/03/2019
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat [...]
Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019
01/03/2019
RALEIGH, N.C., March 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation [...]
Microbot Medical Maintains 2019 Milestone Targets Following Recent Court Decision
01/03/2019
HINGHAM, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) is maintaining its milestone targets for 2019 following the recently announced decision of the New York State Supreme Court to [...]
Akorn Comments on Favorable Court Order
01/03/2019
LAKE FOREST, Ill., March 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) announced today that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG to bring a fraud claim against Akorn. On [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/03/2019
EMERYVILLE, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to five new [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/03/2019
BURLINGTON, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 19,250 shares of common stock [...]
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01/03/2019
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]

Pages